GO:0030195 negative regulation of blood coagulation: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0030195 (negative regulation of blood coagulation) describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of blood clot formation.
• The protein C anticoagulant pathway is a major mechanism for negative regulation of blood coagulation, involving thrombin, thrombomodulin, protein C, protein S, and factor V.
• Protein S serves as a central regulator of blood coagulation by acting as a cofactor for activated protein C and directly inhibiting procoagulant complexes.
• Vitamin K-dependent proteins, including prothrombin and protein C, are critical for balancing procoagulant and anticoagulant activities.
• Dysregulation of negative regulation of blood coagulation contributes to thrombotic disorders, and understanding these pathways is essential for developing targeted therapies.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise dissection of genes involved in negative regulation of blood coagulation.
Description
Blood coagulation is a tightly regulated process that prevents excessive bleeding while avoiding pathological thrombosis. The Gene Ontology term GO:0030195, negative regulation of blood coagulation, encompasses any process that stops, prevents, or reduces the frequency, rate, or extent of blood coagulation. This term is essential for researchers studying hemostasis, thrombosis, and related diseases because it captures the molecular brakes that keep clot formation in check. The protein C anticoagulant pathway is a well-characterized example of negative regulation of blood coagulation, where thrombin switches from a procoagulant to an anticoagulant role upon binding thrombomodulin. Protein S further modulates this pathway by enhancing activated protein C activity and directly inhibiting procoagulant complexes. Understanding the negative regulation of blood coagulation is critical for identifying therapeutic targets in thrombotic disorders and for interpreting genetic variants that affect bleeding and clotting balance.
negative regulation of blood coagulation At A Glance
| GO ID | GO:0030195 |
|---|---|
| GO term | negative regulation of blood coagulation |
| Ontology | biological_process |
| Synonym | down regulation of blood coagulation, down-regulation of blood coagulation, downregulation of blood coagulation, inhibition of blood coagulation |
| Major function | Stops, prevents, or reduces the frequency, rate or extent of blood coagulation |
| Key regulators | Protein C, protein S, thrombomodulin, antithrombin, tissue factor pathway inhibitor |
| Related pathways | Protein C anticoagulant pathway, vitamin K-dependent carboxylation |
| Disease relevance | Thrombosis, disseminated intravascular coagulation, inherited anticoagulant deficiencies |
What Is GO:0030195?
GO:0030195, negative regulation of blood coagulation, is defined as any process that stops, prevents, or reduces the frequency, rate or extent of blood coagulation. It includes molecular mechanisms such as the protein C anticoagulant pathway, which inactivates procoagulant factors, and the action of anticoagulant proteins like protein S that dampen clot formation.
Why Is negative regulation of blood coagulation Important in Cell Biology?
Negative regulation of blood coagulation is vital for maintaining hemostatic balance; its failure leads to thrombotic disorders such as deep vein thrombosis and pulmonary embolism, while excessive activity can cause bleeding. Understanding this process at the molecular level informs the development of anticoagulant drugs and the interpretation of genetic variants in coagulation factors.
• Prevents pathological thrombosis by limiting clot propagation.
• Balances procoagulant and anticoagulant activities to maintain blood fluidity.
• Protein C pathway mutations are linked to venous thromboembolism.
• Protein S deficiency increases risk of thrombosis.
• Vitamin K status affects the function of anticoagulant proteins.
• Provides targets for anticoagulant therapy (e.g., warfarin, direct oral anticoagulants).
• Involved in sepsis-associated coagulopathy and disseminated intravascular coagulation.
• Critical for understanding pregnancy-related coagulation changes.
• Guides interpretation of genetic testing for thrombophilia.
• Enables research on CRISPR-based correction of coagulation disorders.
What Happens During negative regulation of blood coagulation?
Initiation of the protein C anticoagulant pathway
In simple terms: When thrombin is generated, it can bind to thrombomodulin on endothelial cells and switch to an anticoagulant role.
Thrombin, the central enzyme of coagulation, binds to thrombomodulin on the endothelial surface, forming a complex that activates protein C. This activation is a key step in negative regulation of blood coagulation because activated protein C (APC) subsequently inactivates factors Va and VIIIa, slowing clot formation.
Cofactor function of protein S
In simple terms: Protein S helps activated protein C do its job more efficiently.
Protein S acts as a cofactor for APC in the inactivation of factor Va and VIIIa, enhancing the anticoagulant response. Additionally, protein S can directly inhibit prothrombinase and tenase complexes, providing a direct negative regulatory mechanism independent of APC.
Inactivation of procoagulant factors
In simple terms: Activated protein C cuts up factors Va and VIIIa, which are needed for clotting.
APC cleaves and inactivates factor Va and factor VIIIa, thereby reducing the generation of thrombin and fibrin. This proteolytic inactivation is a central mechanism for downregulating blood coagulation.
Role of antithrombin and tissue factor pathway inhibitor
In simple terms: Other proteins like antithrombin and TFPI also put brakes on clotting.
Antithrombin inhibits thrombin and other serine proteases, while tissue factor pathway inhibitor (TFPI) blocks the initiation of coagulation. These inhibitors provide additional layers of negative regulation to prevent excessive clot formation.
Vitamin K-dependent carboxylation and anticoagulant function
In simple terms: Vitamin K is needed to make both clotting factors and anticoagulant proteins work properly.
Vitamin K-dependent gamma-carboxylation is required for the activity of procoagulant factors (e.g., prothrombin) and anticoagulant proteins (e.g., protein C and protein S). This post-translational modification is essential for the negative regulation of blood coagulation because it enables the functional assembly of the protein C pathway.
Key Genes Involved in GO:0030195 negative regulation of blood coagulation
The following genes and proteins are central to the negative regulation of blood coagulation, based on their established roles in anticoagulant pathways and related processes.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PROC | Encodes protein C, zymogen of activated protein C | Mutations cause protein C deficiency and thrombosis |
| PROS1 | Encodes protein S, cofactor for APC | Deficiency leads to thrombophilia |
| THBD | Encodes thrombomodulin, cofactor for thrombin-mediated protein C activation | Mutations linked to atypical hemolytic uremic syndrome |
| SERPINC1 | Encodes antithrombin, inhibits thrombin and factor Xa | Deficiency causes inherited thrombophilia |
| TFPI | Encodes tissue factor pathway inhibitor | Regulates initiation of coagulation |
| F5 | Encodes factor V, substrate for APC | Factor V Leiden mutation causes APC resistance |
| F2 | Encodes prothrombin, precursor of thrombin | Prothrombin G20210A mutation increases thrombosis risk |
| F8 | Encodes factor VIII, substrate for APC | Hemophilia A and APC resistance |
| F9 | Encodes factor IX | Hemophilia B |
| F10 | Encodes factor X | Key procoagulant enzyme |
| F11 | Encodes factor XI | Involved in intrinsic pathway |
| F12 | Encodes factor XII | Contact activation |
| F13A1 | Encodes factor XIII A subunit | Clot stabilization |
| PLG | Encodes plasminogen | Fibrinolysis |
| SERPINE1 | Encodes plasminogen activator inhibitor-1 | Inhibits fibrinolysis |
| MALAT1 | Long non-coding RNA involved in coagulation regulation | Modulates caspase-11 signaling in gram-negative bacteria-induced coagulation |
How Is negative regulation of blood coagulation Regulated?
The negative regulation of blood coagulation is itself regulated at multiple levels. The protein C pathway is modulated by thrombomodulin expression, endothelial protein C receptor (EPCR), and inflammatory mediators. Protein S activity is influenced by its binding to C4b-binding protein and by vitamin K-dependent carboxylation. Additionally, MALAT1 has been shown to regulate gram-negative bacteria-induced coagulation via caspase-11 signaling, linking inflammation to anticoagulant mechanisms.
negative regulation of blood coagulation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PROC | Protein C deficiency, thrombosis | Knockout mouse, point mutation knock-in |
| PROS1 | Protein S deficiency, thrombophilia | Conditional knockout, overexpression |
| F5 | Factor V Leiden, APC resistance | Point mutation knock-in (F5 Leiden) |
| SERPINC1 | Antithrombin deficiency | Knockout, knock-in of deficiency variants |
| MALAT1 | Sepsis-associated coagulopathy | Knockout, overexpression in endothelial cells |
Thrombophilia and venous thromboembolism
Defects in negative regulation of blood coagulation, such as protein C or protein S deficiency, antithrombin deficiency, and factor V Leiden, are major risk factors for venous thromboembolism. These conditions highlight the clinical importance of anticoagulant pathways in preventing pathological clot formation.
Disseminated intravascular coagulation (DIC)
In DIC, widespread activation of coagulation overwhelms negative regulatory mechanisms, leading to both thrombosis and bleeding. The protein C pathway is often impaired in DIC, contributing to poor outcomes.
Pregnancy-related coagulation disorders
Pregnancy is associated with changes in coagulation and anticoagulant proteins, and deficiencies in negative regulation can lead to complications such as recurrent pregnancy loss and preeclampsia.
Inflammation and sepsis
Inflammatory mediators downregulate thrombomodulin and EPCR, impairing the protein C pathway and promoting a procoagulant state. MALAT1 has been implicated in gram-negative bacteria-induced coagulation, linking inflammation to negative regulation.
From negative regulation of blood coagulation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PROC increase thrombosis risk? | PROC knockout mouse |
| Does the factor V Leiden mutation cause APC resistance? | F5 point mutation knock-in mouse |
| Can overexpression of PROS1 enhance anticoagulation? | PROS1 overexpression transgenic mouse |
| What is the role of MALAT1 in bacterial coagulation? | MALAT1 knockout and overexpression cell lines |
| How does thrombomodulin deficiency affect protein C activation? | THBD conditional knockout mouse |
| Can CRISPR correction of SERPINC1 restore antithrombin levels? | Knock-in of wild-type SERPINC1 in patient iPSCs |
How to Study the negative regulation of blood coagulation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| aPTT/PT | Clotting time via intrinsic/extrinsic pathways | Diagnosis of coagulopathies |
| Thrombin generation assay | Overall thrombin production | Assessing hyper- or hypocoagulability |
| ELISA | Antigen levels of protein C, protein S, antithrombin | Deficiency diagnosis |
| Chromogenic assay | Functional activity of anticoagulant proteins | Confirming functional deficiencies |
| DNA sequencing | Mutations in coagulation genes | Genetic testing for thrombophilia |
| CRISPR knockout screen | Genes affecting coagulation phenotype | Discovery of novel regulators |
| RNA-seq | Transcriptional changes in coagulation pathways | Mechanistic studies in disease models |
| Proteomics | Protein abundance and modifications | Identifying biomarkers of coagulation disorders |
Coagulation assays
Activated partial thromboplastin time (aPTT), prothrombin time (PT), and thrombin generation assays measure the overall coagulant capacity and can detect defects in negative regulation.
Genetic and genomic analysis
Next-generation sequencing and targeted genotyping identify mutations in PROC, PROS1, SERPINC1, F5, and F2 that affect negative regulation of blood coagulation.
Protein expression and functional studies
Western blotting, ELISA, and activity assays for protein C, protein S, and antithrombin quantify anticoagulant protein levels and function.
CRISPR-based screens
Genome-wide CRISPR knockout or activation screens can identify novel regulators of blood coagulation in endothelial or hepatic cell models.
How CRISPR Can Be Used to Study GO:0030195 negative regulation of blood coagulation
Knockout
CRISPR knockout of genes such as PROC, PROS1, or SERPINC1 in cell lines or animal models can recapitulate deficiency states and reveal their impact on negative regulation of blood coagulation.
Point Mutation
Introducing specific point mutations (e.g., factor V Leiden, prothrombin G20210A) using CRISPR base editing or homology-directed repair allows precise modeling of genetic variants that impair negative regulation.
Knock-in
Knock-in of wild-type or variant alleles (e.g., tagged protein C) enables tracking of protein localization and function in vivo, providing insights into anticoagulant pathways.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression of anticoagulant genes like PROS1 or THBD can enhance negative regulation and serve as potential therapeutic strategies.
How EDITGENE Supports negative regulation of blood coagulation Research
Researchers studying negative regulation of blood coagulation-related genes often need to determine whether a candidate gene is causally involved in anticoagulant pathways or is merely a biomarker. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such functional studies with high precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of blood coagulation research.
Frequently Asked Questions About negative regulation of blood coagulation
What is negative regulation of blood coagulation?
Negative regulation of blood coagulation (GO:0030195) refers to any process that stops, prevents, or reduces the frequency, rate, or extent of blood clot formation.
What genes are involved in negative regulation of blood coagulation?
Key genes include PROC, PROS1, THBD, SERPINC1, TFPI, and F5, which encode proteins in the protein C anticoagulant pathway and other inhibitory mechanisms.
How does the protein C pathway negatively regulate coagulation?
Thrombin binds thrombomodulin and activates protein C; activated protein C then inactivates factors Va and VIIIa, reducing thrombin generation.
What is the role of protein S in blood coagulation?
Protein S is a cofactor for activated protein C and also directly inhibits procoagulant complexes, making it a central negative regulator.
What diseases are associated with defective negative regulation of blood coagulation?
Deficiencies in protein C, protein S, or antithrombin, and factor V Leiden, cause thrombophilia and increase risk of venous thromboembolism.
How is negative regulation of blood coagulation studied in the lab?
Common methods include coagulation assays (aPTT, PT), thrombin generation, ELISA for anticoagulant proteins, and CRISPR-based genetic screens.
Can CRISPR be used to model negative regulation of blood coagulation?
Yes, CRISPR knockout, point mutation knock-in, and overexpression models allow precise dissection of genes involved in anticoagulant pathways.
What is the role of vitamin K in negative regulation of blood coagulation?
Vitamin K is required for gamma-carboxylation of both procoagulant and anticoagulant proteins, including protein C and protein S, enabling their function.
How does MALAT1 affect blood coagulation?
MALAT1 regulates gram-negative bacteria-induced coagulation via caspase-11 signaling, linking inflammation to anticoagulant mechanisms.
What are the therapeutic implications of targeting negative regulation of blood coagulation?
Enhancing negative regulation could prevent thrombosis, while inhibiting it might manage bleeding disorders; understanding these pathways guides drug development.
Conclusion
GO:0030195 negative regulation of blood coagulation is a critical biological process that maintains hemostatic balance by preventing excessive clot formation. The protein C pathway, protein S, antithrombin, and other inhibitors work in concert to keep coagulation in check. Dysregulation of these mechanisms underlies thrombotic disorders, making them important targets for research and therapy. CRISPR-based models offer powerful tools to dissect the genetic and molecular basis of negative regulation, paving the way for novel anticoagulant strategies.
References
- 2. Norris LA. 2003. Blood coagulation.. Best Pract Res Clin Obstet Gynaecol 17(3):369-83 PMID: 12787532
- 3. Esmon CT. 2000. Regulation of blood coagulation.. Biochim Biophys Acta 1477(1-2):349-60 PMID: 10708869
- 4. Yuan C et al.. 2026. A critical role for MALAT1 in gram-negative bacteria-induced coagulation via regulation of caspase-11 signaling.. J Thromb Haemost 24(3):1014-1031 PMID: 41391567
- 5. Alshaikh NA. 2022. Protein S: a Central Regulator of Blood Coagulation.. Clin Lab 68(8) PMID: 35975485
- 6. Halder M et al.. 2019. Vitamin K: Double Bonds beyond Coagulation Insights into Differences between Vitamin K1 and K2 in Health and Disease.. Int J Mol Sci 20(4) PMID: 30791399
- 7. Dahlbäck B et al.. 2005. Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition.. Arterioscler Thromb Vasc Biol 25(7):1311-20 PMID: 15860736
